Retinal Vein Occlusion - Pipeline Insight, 2024

Retinal Vein Occlusion - Pipeline Insight, 2024

DelveInsight’s, “Retinal Vein Occlusion – Pipeline Insight, 2024,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Retinal Vein Occlusion pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Retinal Vein Occlusion Understanding

Retinal Vein Occlusion: Overview

Retinal vein occlusion (RVO) is the second most common retinal vascular disease and is a common loss of vision in older patients. There are two types of RVO: Branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO). Central retinal vein occlusion is an occlusion of the main retinal vein posterior to the lamina cribrosa of the optic nerve and is typically caused by thrombosis. Central retinal vein occlusion is further divided into two categories: non-ischemic (perfused) and ischemic (nonperfused). Non-ischemic CRVO is the most common, accounting for about 70% of cases. A primary risk factor for the development of central retinal vein occlusion is age, with 90% of patients older than 50 years old. Systemic arterial hypertension, open-angle glaucoma, diabetes mellitus, and hyperlipidemia have all been implicated as other primary risk factors for central retinal vein occlusion. Other associated risk factors include smoking, optic disc drusen, optic disc edema, hypercoagulable state (polycythemia, multiple myeloma, cryoglobulinemia, Waldenstrom macroglobulinemia, antiphospholipid syndrome, Leiden factor V, activated protein C resistance, hyperhomocysteinemia, Protein C and S deficiency, antithrombin III mutation, prothrombin mutation), syphilis, sarcoidosis, African American race, sickle cell, HIV, vasculitis, drugs such as oral contraceptives or diuretics, abnormal platelet function, orbital disease, and rarely migraines.

No totally effective medical treatment is available for either the prevention or treatment of central retinal vein occlusion. Surgical interventions include laser photocoagulation, chorioretinal venous anastomosis, radial optic neurotomy, and vitrectomy. There are specific surgical and laser approaches have been found to potentially improve visual acuity in patients with central retinal vein occlusion. Pars plana vitrectomy (PPV) can be done when central retinal vein occlusions have an associated vitreous hemorrhage. PPV may be used to clear the hemorrhage from the visual axis and allows for better visualization of the retina. A PPV may also ablate neovascularization that can cause neovascular glaucoma in the anterior segment. Laser pan-retinal photocoagulation (PRP) can be done to treat neovascularization, with the goal of devitalizing some of the retinal tissue to prevent further neovascularization and treat iris neovascularization. There is no evidence at this time supporting prophylactic PRP without neovascularization.

Retinal Vein Occlusion Emerging Drugs Chapters

This segment of the Retinal Vein Occlusion report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Retinal Vein Occlusion Emerging Drugs

● KSI-301: Kodiak sciences

The therapeutic candidate KSI-301, currently in clinical development, is a novel anti-VEGF biologic designed to have an extended ocular half-life. Ischemia due to vein occlusion results in secretion of vascular endothelial growth factor (VEGF) that causes further vascular leakage and edema. Anti-VEGF agents have become a very common treatment to improve the clinical outcomes in patients with RVO. As in wet AMD, an intensive treatment frequency is required to achieve optimal outcomes with currently-approved anti-VEGFs agents. However, many patients are lost to follow up due to the frequent injections and real-world outcomes in RVO do not meet the promise shown in clinical trials. By extending the on-mechanism treatment interval, KSI-301 may relieve the high treatment burden for patients, their family members, and physicians. KSI-301 is being developed in Phase III stage of development towards a once every two months or longer treatment regimen.

● 601: Sunshine Guojian Pharmaceutical

601A is a recombinant humanized anti-VEGF monoclonal antibody for injection. The proposed main indications are age-related macular degeneration and diabetic macular edema and retinal vein occlusion; and it is currently in Phase II clinical trials.

● IBE-814: Ripple Therapeutics

IBE-814 is designed to deliver a low, consistent, efficacious dose for approximately six to nine months. The goal is to extend clinical benefit while decreasing common steroid-induced adverse events. RIPPLE-1 is a phase II, multi-center, single-masked dose-ranging study designed to evaluate the safety and efficacy of two dosage regimens of IBE-814 IVT in patients with diabetic macular edema (DME) or macular edema due to retinal vein occlusion (RVO).

Further product details are provided in the report……..

Retinal Vein Occlusion: Therapeutic Assessment

This segment of the report provides insights about the different Retinal Vein Occlusion drugs segregated based on following parameters that define the scope of the report, such as:

● Major Players in Retinal Vein Occlusion

There are approx. 15+ key companies which are developing the therapies for Retinal Vein Occlusion. The companies which have their Retinal Vein Occlusion drug candidates in the mid to advanced stage, i.e. Phase III include, Kodiak sciences

Phases

DelveInsight’s report covers around 15+ products under different phases of clinical development like

• Late-stage products (Phase III )
• Mid-Stage products (Phase II)
• Early-stage products ( Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

● Route of Administration

Retinal Vein Occlusion pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Oral

● Molecule Type

Products have been categorized under various Molecule types such as

• Small molecules
• Peptide
• Antibiotics

● Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Retinal Vein Occlusion: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Retinal Vein Occlusion therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Retinal Vein Occlusion drugs.

Report Highlights

● The companies and academics are working to assess challenges and seek opportunities that could influence Retinal Vein Occlusion R&D. The therapies under development are focused on novel approaches to treat/improve Retinal Vein Occlusion.

Retinal Vein Occlusion Report Insights

• Retinal Vein Occlusion Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Retinal Vein Occlusion Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Retinal Vein Occlusion drugs?
• How many Retinal Vein Occlusion drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Retinal Vein Occlusion?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Retinal Vein Occlusion therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Retinal Vein Occlusion and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Kodiak Sciences
• Hoffman-La-Roche
• iRenix Medical, Inc.
• Sunshine Guojian Pharmaceutical
• Ripple Therapeutics
• Aerpio Therapeutics
• The Emmes Company
• Novartis
• Shanghai BDgene
• AsclepiX Therapeutics
• Taiwan Liposome Company
• Clearside Biomedical
• Gene Signal
• Ocular Therapeutix
• Ocuphire Pharma
• Eyevensys

Key Products

• KSI-301
• Faricimab
• IRX-101
• 601
• IBE-814
• AKB-9778
• Autologous Bone Marrow CD34+ Stem Cells
• MHU650
• BD311
• TLC399
• CLS-TA
• APX 3330
• EYS809
• Aganirsen
• Brolucizumab